Aspirin Dosing for Peripheral Arterial Disease Revascularization

Pre‑Procedure Loading Dose

Aspirin‑naïve patients should receive a 325 mg non‑enteric‑coated aspirin loading dose as early as possible before revascularization (preferably ≥2 h, ideally 24 h, to ensure adequate platelet inhibition) – American Heart Association/American College of Cardiology (Circulation 2011; 2006) [1][2]
Non‑enteric‑coated formulation is required for rapid absorption and immediate antiplatelet effect – American Heart Association/American College of Cardiology (Circulation 2014) 3
Patients already on aspirin should continue their existing daily dose (81–325 mg) without interruption – American Heart Association/American College of Cardiology (Circulation 2011) 1

Post‑Revascularization Maintenance Therapy

Indefinite low‑dose aspirin (81 mg daily) is recommended after peripheral arterial revascularization – American Heart Association/American College of Cardiology (Circulation 2011; JACC 2013) [1][4]
Higher doses (up to 325 mg) are acceptable but do not improve cardiovascular protection and are associated with significantly higher bleeding risk – American Heart Association/American College of Cardiology (Circulation 2014; European Heart Journal 2024) [3][5]

Timing Considerations

If the optimal 2–24 h loading window cannot be met, aspirin should be administered “as soon as possible” before the procedure – American Heart Association/American College of Cardiology (Circulation 2011) 1
Administering aspirin too close to the procedure may fail to achieve adequate platelet inhibition – American Heart Association/American College of Cardiology (Circulation 2011) 1
When fibrinolytic therapy is used, a clopidogrel loading dose of 300 mg within 24 h (or 600 mg after 24 h) is advised – American Heart Association/American College of Cardiology (Circulation 2011) 1

Safety and Contraindications

Enteric‑coated aspirin should be avoided for loading because it delays and reduces absorption – American Heart Association/American College of Cardiology (Circulation 2014) 3
Full‑intensity oral anticoagulation (e.g., warfarin) as monotherapy is not recommended for PAD without another indication, due to increased bleeding without reduction in MACE or MALE – American Heart Association/American College of Cardiology (Circulation 2014) 3
Routine use of ticagrelor in PAD patients is not recommended – European Society of Cardiology (European Heart Journal 2024) 5
Antiplatelet therapy is not indicated for asymptomatic PAD unless there is clinically relevant atherosclerotic cardiovascular disease – European Society of Cardiology (European Heart Journal 2024) 5

Guideline Recommendations (2024 ESC PAD Guidelines)

Aspirin 75–160 mg daily is the guideline‑endorsed dose for symptomatic PAD patients – European Society of Cardiology (European Heart Journal 2024) 5
Long‑term dual antiplatelet therapy is not routinely recommended because it increases bleeding without clear benefit – European Society of Cardiology (European Heart Journal 2024) 5

Evidence quality is primarily extrapolated from percutaneous coronary intervention data and reinforced by recent PAD‑specific guidelines. – American Heart Association/American College of Cardiology (Circulation 2014; 2011; 2006; JACC 2008; JACC 2013) and European Society of Cardiology (European Heart Journal 2024) [3][1][2][6][4][5]

Aspirin and Antithrombotic Management for Peripheral Arterial Disease Revascularization

Pre‑Operative Aspirin Dosing

For patients undergoing peripheral arterial revascularization who are not already on aspirin, administer a 325 mg dose of non‑enteric‑coated aspirin as soon as possible before the procedure; patients already taking aspirin should continue their daily dose of 81–325 mg. 7
In aspirin‑naïve patients, a 325 mg non‑enteric‑coated aspirin dose should be given pre‑operatively. 8, 9, 10
The loading dose should be given at least 2 hours before the procedure, with a preferred window of 24 hours in advance to allow optimal platelet inhibition. 11
A higher loading dose (300–325 mg) is specifically recommended for aspirin‑naïve patients to achieve rapid platelet inhibition. 11, 12
Patients already on a daily aspirin regimen should continue their current dose of 81–325 mg before the procedure. 13, 8, 10
Aspirin should not be discontinued in the peri‑operative period. 7
A non‑enteric‑coated formulation is preferred for more rapid absorption when aspirin is given pre‑operatively. 8, 9

Post‑Revascularization Maintenance

After peripheral arterial revascularization, aspirin should be continued indefinitely at a daily dose of 81–325 mg. 13, 7
For long‑term maintenance, low‑dose aspirin (≈81 mg daily) is preferred to reduce bleeding risk while preserving cardiovascular protection. 14, 13, 12
Evidence shows that a daily dose of 75–81 mg provides cardiovascular outcomes equivalent to 325 mg but with significantly fewer bleeding complications. 14

Combination Antithrombotic Therapy (Endovascular Revascularization)

Adding low‑dose rivaroxaban 2.5 mg twice daily to aspirin is recommended to reduce major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after endovascular procedures. 7

Dual Antiplatelet Therapy (DAPT)

After endovascular revascularization, a regimen of clopidogrel 75 mg daily plus low‑dose aspirin for 1–6 months is reasonable. 7
Following surgical revascularization with prosthetic grafts, DAPT may be reasonable for at least 1 month. 7

Timing Considerations for Aspirin Loading

The optimal 2–24 hour window for aspirin loading in aspirin‑naïve patients is important; administering aspirin too close to the procedure may not achieve adequate platelet inhibition. 11
If the ideal timing window cannot be met, “as soon as possible” administration is still recommended. 8, 9

Anticoagulation Guidance

Full‑intensity oral anticoagulation should not be used in PAD patients without another indication (e.g., atrial fibrillation) because it does not reduce MACE or MALE and markedly increases bleeding risk; the low‑dose rivaroxaban + aspirin combination offers a safer, evidence‑based alternative. 7